Cytosorbents Corporation (CTSO) vs Kiora Pharmaceuticals, Inc. (KPRX)
A side-by-side comparison of Cytosorbents Corporation and Kiora Pharmaceuticals, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
CTSO
Cytosorbents Corporation
$4.08HealthcareDelayed quote: Oct 6, 2026, 1:07 PM EDT
KPRX
Kiora Pharmaceuticals, Inc.
$2.51HealthcareDelayed quote: Oct 6, 2026, 1:20 PM EDT
Total return — CTSO vs KPRX
growth of $100 · dividends reinvested · last 10yCTSO -97.1% (-29.7%/yr)KPRX -100.0% (-56.0%/yr)CTSO compounded faster over this window
Log scale — wide-divergence pair
CTSO KPRX
CTSO vs KPRX: by the numbers
- •CTSO is the larger company ($13M vs $11M market cap).
- •Both run net losses; KPRX's is the smaller (0.00% vs -48.94% net margin).
Metrics side by side
Valuation
| Metric | CTSO | KPRX |
|---|---|---|
| P/S ratio | 0.34 | N/A |
| P/B ratio | N/A | 0.66 |
Profitability
| Metric | CTSO | KPRX |
|---|---|---|
| Gross margin | 71.61% | 0.00% |
| Operating margin | -33.37% | 0.00% |
| Net margin | -48.94% | 0.00% |
| ROE | N/A | -65.18% |
| ROIC | -43.31% | -59.42% |
Growth (annualized)
| Metric | CTSO | KPRX |
|---|---|---|
| Revenue CAGR (5Y) | -3.17% | N/A |
| Total return CAGR (5Y) | -52.26% | -67.06% |
Frequently asked
- How have CTSO and KPRX total returns compared?
- Over the past 10 years, CTSO delivered -28.72% and KPRX delivered -55.97% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.